Adverse events after mass azithromycin treatments for trachoma in Ethiopia.
Author(s): Ayele B, Gebre T, House JI, Zhou Z, McCulloch CE, Porco TC, Gaynor BD, Emerson PM, Lietman TM, Keenan JD
Affiliation(s): The Carter Center, Addis Ababa, Ethiopia.
Publication date & source: 2011-08, Am J Trop Med Hyg., 85(2):291-4.
Publication type: Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
During a cluster-randomized clinical trial for trachoma in Ethiopia, two rounds of adverse event surveillance were performed in a random sample of communities after community-wide mass azithromycin treatment. The prevalence of any reported adverse event ranged from 4.9% to 7.0% in children 1-9 years of age and from 17.0% to 18.7% in persons >/= 10 years of age. Adverse events appeared to cluster by household and perhaps by village. Mass azithromycin distributions were well tolerated in this setting.